Fmr LLC cut its stake in shares of Axonics, Inc. (NASDAQ:AXNX – Free Report) by 4.3% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 2,601,013 shares of the company’s stock after selling 117,780 shares during the period. Fmr LLC owned approximately 5.16% of Axonics worth $141,911,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of AXNX. Norges Bank acquired a new position in Axonics during the 4th quarter worth approximately $76,440,000. Vanguard Group Inc. lifted its position in Axonics by 32.2% during the 3rd quarter. Vanguard Group Inc. now owns 4,073,473 shares of the company’s stock worth $286,935,000 after acquiring an additional 991,055 shares in the last quarter. Jane Street Group LLC lifted its position in Axonics by 105.4% during the 3rd quarter. Jane Street Group LLC now owns 20,413 shares of the company’s stock worth $1,438,000 after acquiring an additional 400,801 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Axonics during the 4th quarter worth approximately $11,268,000. Finally, Bellevue Group AG raised its position in shares of Axonics by 9.5% in the 1st quarter. Bellevue Group AG now owns 2,049,205 shares of the company’s stock valued at $128,280,000 after purchasing an additional 177,191 shares in the last quarter. 99.00% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, insider Alfred J. Ford, Jr. sold 14,769 shares of the company’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $62.34, for a total transaction of $920,699.46. Following the completion of the transaction, the insider now directly owns 34,565 shares in the company, valued at approximately $2,154,782.10. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, insider Alfred J. Ford, Jr. sold 14,769 shares of the stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $62.34, for a total value of $920,699.46. Following the completion of the transaction, the insider now owns 34,565 shares of the company’s stock, valued at $2,154,782.10. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Alfred J. Ford, Jr. sold 1,500 shares of the stock in a transaction on Friday, July 28th. The stock was sold at an average price of $62.01, for a total value of $93,015.00. Following the completion of the transaction, the insider now directly owns 49,334 shares of the company’s stock, valued at approximately $3,059,201.34. The disclosure for this sale can be found here. 1.85% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
View Our Latest Stock Report on AXNX
Axonics Trading Up 1.2 %
Shares of NASDAQ AXNX opened at $58.00 on Friday. Axonics, Inc. has a twelve month low of $47.59 and a twelve month high of $79.92. The company has a market capitalization of $2.93 billion, a price-to-earnings ratio of -86.57 and a beta of 0.41. The business has a 50 day simple moving average of $55.01 and a 200-day simple moving average of $54.73.
Axonics (NASDAQ:AXNX – Get Free Report) last issued its quarterly earnings data on Thursday, July 27th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). The company had revenue of $92.90 million for the quarter, compared to the consensus estimate of $86.45 million. Axonics had a negative return on equity of 5.60% and a negative net margin of 10.06%. Axonics’s quarterly revenue was up 34.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.47) earnings per share. As a group, equities analysts predict that Axonics, Inc. will post -0.35 earnings per share for the current year.
Axonics Profile
Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction.
See Also
- Five stocks we like better than Axonics
- What Are the U.K. Market Holidays? How to Invest and Trade
- MarketBeat Week in Review – 8/28 – 9/1
- Industrial Products Stocks Investing
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- Investing in the Best Airline Stocks
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for Axonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics and related companies with MarketBeat.com's FREE daily email newsletter.
